v3 Template
A

Athernal Bio

Biotechnology / Healthcare ~300 employees
Founded
--
Employees (Est.)
~300
15 leaders known
Total Funding
$4.5M
Funding Rounds
1
Last Funding
2025-10-01

About Athernal Bio

Athernal Bio is a biotechnology company focused on developing the first targeted immunotherapies for high-risk clonal haematopoiesis, a blood cancer precursor condition. Their mission is to stop cancer before it starts through early and proactive therapeutic intervention.

Products & Services

ath-001:Targeted immunotherapy for rare blood disorders with accelerated clonal haematopoiesis (CH) and acute myeloid leukemia (AML) risk.
ath-002:Targeted immunotherapy for cytotoxic injury in cancer survivors post-chemotherapy and radiotherapy.

Specialties

Immunotherapy Clonal Haematopoiesis Blood Cancer Prevention Oncology

Funding History

Debug: View Raw Funding Data
# Type Amount Fields Date Fields Investors
1 RT: Seed
T: -
FT: Seed 		A: 4550000
MR: -
FA: £3.5 million
FAN: 4550000 		D: 2025-10-01
FD: 2025-10-01 		1 investors
Seed Latest
2025-10-01
$4.5M
1 investor (Pro only)

Growth Metrics

+45%
Employee Growth
YoY
3.2x
Funding Growth
Last Round
12
Markets
Operating
10K+
Customers
Active

View 3 more growth metrics with Pro

Unlock All Metrics
Mock Up

Team & Leadership

C

Colin Freund

Chief Executive Officer

LinkedIn (Pro only)
N

Nirupa Desai

Founder & Chief Scientific Officer

LinkedIn (Pro only)
I

Ieuan Walker

Founder & Board Observer

LinkedIn (Pro only)
C

Caroline Haegeman

Chief Operating Officer

N

Nigel Horscroft

Chief Technology Officer

Z

Zahid Bashir

Chief Medical Officer

View 12 more team members with Pro

Unlock Full Team Directory

Recent News

Athernal Bio Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Read more →

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Read more →

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Read more →

View 2 more news articles with Pro

Unlock Full News Feed
Mock Up

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised

Mock Up

Company Details

Industries
Biotechnology / Healthcare
Company Size
~300 employees (est.)

Technology Stack

Discover the backend, frontend, and infrastructure technologies powering this company's products.

Upgrade to Pro